Progenics Cord Blood Cryobank Inc. 416-221-1666


Why Save Cord Blood?

Cord blood is rich in hematopoietic (blood-forming) stem cells

Bone marrow transplantation is a definitive or adjuvant therapy for patients with otherwise life-threatening diseases; however, finding a suitable bone marrow donor in a timely manner when a patient requires a transplant can be extremely difficult. Cord blood has the same types of stem cells as those found in bone marrow. The cells in cord blood can therefore be used as an alternative to bone marrow stem cells to save the lives of patients. 

It contains valuable, therapeutic stem cells

  • Unrestricted somatic stem cells (USSC)
    The discovery of unrestricted somatic stem cells (USSC), a non-hematopoietic stem cell population, brought cord blood (CB) to the forefront of regenerative medicine, a new field that uses cord blood to repair damaged tissues and organs.
  • Mesenchymal stem cells (MSC)
    Mesenchymal stem cells are multipotent stem cells that can differentiate into a variety of cell types, such as osteoblasts (bone cells), chondrocytes (cartilage cells) and adipocytes (fat cells) and more.
  • Endothelial progenitor cells (EPC)
    The use of human cord-blood-derived EPCs is quite attractive for induction of angiogenesis in critically ischemic diseases.

It has been successfully used to treat many types of life-threatening diseases

Stem cells have been used to treat many types of malignant and non-malignant life-threatening diseases. Cord blood stem cells have saved the lives of over forty thousand patients worldwide.

It has been recommended that transplanting cord blood stem cells with a perfect HLA match should be the first choice over bone marrow to treat malignant diseases (Smith A. and Wagner J. BJH147, 246–261, 2009).

It has been used in clinical trials to repair damaged tissues and organs, and the outcomes have been promising

With advances in research on cord blood and clinical trials, it has shown promising outcomes in repairing damaged tissues and organs for treatment of diabetes, heart disease, liver disease, spinal cord injury, brain injury and more.

> List of all treatable malignant and non-malignant diseases

Autologous transplantation of cord blood could become an important therapy

  • It is increasing much faster than allogeneic transplantation
    The rising rate of autologous therapy (treatment with the baby’s own cord blood stem cells) exceeds exponential growth, compared with linear growth in the number of allogeneic cord blood transplants being performed (NMDP) since 2006 (treatment with cord blood stem cells donated by others) (Verter F and Nietfeld J. Cytotherapy Vol.12 Supplement 1, 2010 (abstract)).

Banking cord blood at birth is a once-in-a-lifetime opportunity

Cord blood can only be collected at birth but the life saving potential of these valuable cells can last a life-time. More importantly, cord blood stem cells from a family member are better for transplant to a patient than stem cells from an unrelated donor and this could be the most significant factor contributing to a full recovery.